natgillin/translations-raw huggingface dataset:
Alopecia, eczema, pruritus,
Alopecija, ekcem, pruritis
Levetiracetam Teva 750 mg contains Sunset Yellow
Levetiracetam Teva 750 mg sadrži sunset yellow
The patients were randomized to carbamazepine CR 400 - 1200 mg/day or levetiracetam 1000 - 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.
Bolesnici su randomizirani za dobivanje 400 -1200 mg karbamazepina s kontroliranim otpuštanjem (CR) na dan ili 1000 -3000 mg levetiracetama na dan, liječenje je trajalo do 121 tjedna, ovisno o odgovoru.
In vitro, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 AND UGT1A6) and epoxide hydroxylase activities.
In vitro je pokazano da levetiracetam i njegov glavni metabolit ne inhibiraju aktivnost glavnih izoformi humanog citokroma P450 (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 i 1A2), glukuronil transferaze
• nasopharyngitis;
• nazofaringitis;
Tablet core: maize starch, povidone, croscarmellose sodium and magnesium stearate.
Jezgra tablete: kukuruzni škrob, povidon, umrežena karmelozanatrij i magnezijev stearat.
Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinylestradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified.
Levetiracetam primijenjen u dozi od 1000 mg na dan nije utjecao na farmakokinetiku oralnih kontraceptiva (etinil-estradiola i levonorgestrela); endokrini pokazatelji (luteinizirajući hormon i progesteron) ostali su nepromijenjeni.
Levetiracetam Teva contains Sodium
Levetiracetam Teva sadrži natrij
305, 74770 Opava-Komarov
Ostravska 29, c.p. 305, 74770 Opava-Komarov
A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1800 mg/kg/day.
Studija peri- i postnatalnog razvoja provedena je u štakora dozama levetiracetama od 70, 350 i 1800 mg/kg/dan.
In this study, levetiracetam dose was 3000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses.
Doza levetiracetama u toj studiji bila je 3000 mg na dan za odrasle i adolescente, a za djecu 60 mg/kg/dan, podijeljena na dvije doze.
In this study, patients were prescribed 20 mg/kg, 25 mg/kg, 40 mg/kg or 50 mg/kg daily dose of oral solution based on their age titration schedule.
U toj je studiji bolesnicima propisana oralna otopina u dnevnoj dozi od 20 mg/kg, 25 mg/kg, 40 mg/kg ili 50 mg/kg prema shemi titriranja ovisnoj o dobi.
Due to its complete and linear absorption, plasma levels can be predicted from the oral dose of levetiracetam expressed as mg/kg bodyweight.
Uslijed potpune i linearne apsorpcije levetiracetama, moguće je na temelju oralne doze izražene u mg/kg tjelesne težine predvidjeti razinu lijeka u plazmi.
In infants and children aged 1 month to less than 4 years, irritability (very common, 11.7%) and coordination abnormal (common, 3.3%) were reported more frequently than in other age groups or in the overall safety profile.
razdražljivost (vrlo često, 11,7%) i poremećaji koordinacije (često, 3,3%) bili su prijavljeni češće nego u drugim dobnim skupinama ili u cjelokupnom sigurnosnom profilu.
In all of the above cases an oral solution should be used.
U svim tim slučajevima treba primijeniti oralnu otopinu.
Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy.
Djelotvornost levetiracetama za samostalno liječenje dokazana je kod paralelnih grupa u dvostruko slijepoj usporedbi neinferiornosti s karbamazepinom s kontroliranim otpuštanjem (CR, controlled release) na 576 bolesnika u dobi od 16 godina ili starijih s novo- ili nedavno dijagnosticiranom epilepsijom.
An oral solution is a formulation more appropriate to infants and children under the age of 6 years and to children and adolescent (from 6 to 17 years) weighing less than 50 kg and when tablets don't allow accurate dosage.
Oralna otopina je prikladniji farmaceutski oblik za primjenu u dojenčadi i djece mlađe od 6 godina, djece i adolescenata (6 - 17 godina) tjelesne težine manje od 50 kg te kada se tabletama ne može postići točno doziranje.
If stopping treatment, Levetiracetam Teva should be discontinued gradually to avoid an increase of seizures.
Ako prekidate liječenje Levetiracetamom Teva prekid mora biti postupan kako bi se izbjeglo pojačanje napadaja.
The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.
Sigurnost i djelotvornost levetiracetama u monoterapiji u djece i adolescenata mlađih od 16 godina nisu ustanovljene.
If you forget to take Levetiracetam Teva
Ako ste zaboravili uzeti Levetiracetam Teva
• Dose in adults and adolescents (12 to 17 years) weighing 50 kg or more:
• Doza u odraslih i adolescenata (12 do 17 godina) koji imaju 50 kg ili više:
Take the number of tablets following your doctor's instructions.
Uzmite onoliko tableta koliko je liječnik propisao.
Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg/kg/day.
Četiri studije embrio-fetalnog razvoja provedene su u kunića s dozama od 200, 600, 800, 1200 i 1800 mg/kg/dan.
The tablet formulation is not adapted for use in infants and children under the age of 6 years.
Farmaceutski oblik tableta nije prilagođen za primjenu u dojenčadi i djece mlađe od 6 godina.
The primary measure of effectiveness was the responder rate (percent of patients with ≥ 50 % reduction from baseline in average daily partial onset seizure frequency) assessed by a blinded central reader using a 48-hour video EEG.
Primarna mjera učinkovitosti bila je stopa bolesnika s odgovorom (postotak bolesnika u kojih je dnevna prosječna učestalost napadaja smanjena za ≥ 50% u odnosu na početno stanje) određena središnjim pregledavanjem 48-satnog video EEG-a od strane ocjenjivača koji nije znao tko je dobivao placebo, a tko lijek.
Levetiracetam Teva are available in pack sizes of 20, 30, 50, 60, 100, 120 and 200 film-coated tablets and 50 x 1 film-coated tablets in PVC/PVdC - aluminium perforated unit dose blisters.
Levetiracetam Teva je dostupan u pakiranju od 20, 30, 50, 60, 100, 120 i 200 filmom obloženih tableta i 50 x 1 filmom obloženih tableta u PVC/PVdC-aluminij perforiranim blisterima djeljivim na jedinične doze.
Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years), levetiracetam was rapidly absorbed.
Nakon ponovljene primjene oralne doze (20 do 60 mg/kg/na dan) u djece s epilepsijom (4 do 12 godina), levetiracetam se brzo apsorbira.
Levetiracetam Teva 500 mg contains the colouring agent tartrazine (E102) that may cause allergic reactions.
Levetiracetam Teva 500 mg sadrži bojilo tartrazin (E102) koje može uzrokovati alergijske reakcije.
Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was 6.0 hours.
Nakon primjene jedne oralne doze (20 mg/kg) u djece s epilepsijom (6 do 12 godina), poluvrijeme života levetiracetama bio je 6,0 sati.
Pack sizes of 20, 30, 50, 60, 100, 120 and 200 film-coated tablets and 50 x 1 film-coated tablets in PVC/PVdC - aluminium perforated unit dose blisters.
Veličine pakiranja od 20, 30, 50, 60,100, 120 i 200 filmom obloženih tableta i 50 x 1 filmom obloženih tableta u PVC/PVdC-aluminij perforiranim blisterima djeljivim na jedinične doze.
Levetiracetam Teva 750 mg contains the colouring agent sunset yellow (E110) that may cause allergic reactions.
Levetiracetam Teva 750 mg sadrži bojilo sunset yellow (E110) koje može uzrokovati alergijske reakcije.
Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening).
Djelotvornost levetiracetama dokazana je u dvostruko slijepoj i placebom kontroliranoj studiji u trajanju od 24 tjedna koja je uključivala odrasle, adolescente i ograničeni broj djece s idiopatskom generaliziranom epilepsijom s primarno generaliziranim toničko-kloničkim (PGTK) napadajima kod različitih sindroma (juvenilna mioklonična epilepsija, epilepsija s apsansima dječje i juvenilne dobi ili epilepsija s grand mal napadajima kod buđenja).
A dose of 20 mg/kg/day titrating to 40 mg/kg/day for infants one month to less than six months and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for infants and children 6 months to less than 4 years old, was use in this study.
Doza od 20 mg/kg/dan titrirana je do 40 mg/kg/dan u dojenčadi u dobi od jednog do manje od 6 mjeseci, a doza od 25 mg/kg/dan titrirana je do 50 mg/kg/dan u dojenčadi i djece u dobi od 6 mjeseci do manje od 4
Following single dose administration (20 mg/kg) of a 100 mg/ml oral solution to epileptic children (1 month to 4 years), levetiracetam was rapidly absorbed and peak plasma concentrations were observed approximately 1 hour after dosing.
Nakon primjene jedne doze (20 mg/kg) 100 mg/ml oralne otopine u djece s epilepsijom (1 mjesec do 4 godine), levetiracetam se brzo apsorbira te je vršna koncentracija u plazmi postignuta približno 1 sat nakon uzimanja lijeka.
For children 6 years and above, an oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets.
U djece od 6 godina i starije, oralnu otopinu treba primjenjivati za doze ispod 250 mg, doze koje nisu višekratnici od 250 mg, odnosno kada preporučeno doziranje ne može biti postignuto uzimanjem većeg broja tableta te u bolesnika koji ne mogu gutati tablete.
The pharmacokinetic profile is linear with low intra- and inter-subject variability.
Farmakokinetički profil je linearan, a varijabilnost je niska, i među različitim bolesnicima, i za istog bolesnika.
7 to 14 mg/kg once daily (2) (4)
7 do 14 mg/kg jedanput na dan (2) (4)
How to take Levetiracetam Teva
Kako uzimati Levetiracetam Teva
43.6 % of the levetiracetam treated patients and 19.6 % of the patients on placebo were considered as responders.
U 44,6% bolesnika liječenih levetiracetamom i 19,6% bolesnika koji su dobivali placebo zapaženo je
You should continue Levetiracetam Teva treatment for as long as your doctor has told you.
Levetiracetamom Teva onoliko dugo koliko je liječnik odredio.
Two embryo-foetal development (EFD) studies were performed in rats at 400, 1200 and 3600 mg/kg/day.
Provedene su dvije studije embrio-fetalnog razvoja (engl. embryo-fetal development, EFD) u štakora s dozama od 400, 1200 i 3600 mg/kg/dan.
The maximum dose is 1500 mg twice daily.
Maksimalna je doza 1500 mg dva puta na dan.
*The colourants are: 250 mg film-coated tablets: brilliant blue FCF (E133) and indigotine (E132).
250 mg filmom obložene tablete: brilliant blue FCF (E133) i indigotin (E132).
This medicinal product contains colouring agent sunset yellow (E110) which may cause allergic reactions.
Ovaj lijek sadrži bojilo sunset yellow (E110) koje može uzrokovati alergijske reakcije.
Levetiracetam has minor or moderate influence on the ability to drive and use machines.
Levetiracetam malo ili umjereno utječe na sposobnost upravljanja vozilima i rada sa strojevima.
• Levetiracetam Teva is used as a chronic treatment.
• Levetiracetam Teva se koristi za dugotrajno liječenje.
This medicinal product contains colouring agent sunset yellow E 110 (see leaflet for further information).
Ovaj lijek sadrži bojilo sunset yellow (E 110) (vidjeti uputu o lijeku za dodatne informacije).
The most frequently reported side effects are nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness.
Najčešće prijavljene nuspojave bile su nazofaringitis, somnolencija (izrazita pospanost), glavobolja, umor i omaglica.
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6 - 17 the MRHD on a mg/m2 basis).
Neonatalne i juvenilne studije na štakorima i psima pokazale su da nema nuspojava u uobičajenim mjerama ishoda razvoja ili sazrijevanja kod primjene doza do 1800 mg/kg/dan (6-erostruka do 17erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
10 to 20 mg/kg once daily (3) (5)
10 do 20 mg/kg jednaput na dan (3) (5)
The efficacy analysis consisted of 109 patients who had at least 24 hours of video EEG in both baseline and evaluation periods.
Analizom djelotvornosti obuhvaćeno je 109 bolesnika u kojih je snimljen barem24-satni EEG na početku i na kraju razdoblja procjene.
• Dose in infants (1 month to 23 months), children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg:
• Doza u dojenčadi (1 mjesec do 23 mjeseca), djece (2 do 11 godina) i adolescenata (12 do 17 godina) koji imaju manje od 50 kg:
Very common: may affect more than 1 in 10 people
Vrlo često: mogu se javiti u više od 1 na 10 ljudi
Levetiracetam and related analogs show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy.
Levetiracetam i srodni analozi različitim se afinitetom vežu za sinaptički vezikularni protein 2A, a to je, u mišjem modelu audiogene epilepsije, povezano s potencijalom zaštite od napada.
In paediatric patients (1 month to less than 4 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 116 patients and had a treatment duration of 5 days.
U pedijatrijskih bolesnika (1 mjesec do manje od 4 godine života) djelotvornost levetiracetama dokazana je dvostruko slijepom i placebom kontroliranom studijom u 116 bolesnika koji su lijek dobivali 5 dana.
(1)An oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets.
(1)Za doze ispod 250 mg, za doze koje nisu višekratnici od 250 mg, odnosno kada preporučeno doziranje ne može biti postignuto uzimanjem većeg broja tableta i kod bolesnika koji ne mogu gutati tablete treba koristiti oralnu otopinu.
With continued long-term treatment, 47.4 % of the patients were free of tonic-clonic seizures for at least 6 months and 31.5 % were free of tonic-clonic seizures for at least 1 year.
S nastavkom dugotrajnog liječenja, 47,4% bolesnika bilo je barem 6 mjeseci i 31,5% barem 1 godinu bez toničko-kloničkih napadaja.
As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day levetiracetam.
Kako ni u odraslih, tako ni u pedijatrijskih bolesnika koji su dobivali do 60 mg/kg/dan levetiracetama,
Dosing adjustment for adult and adolescent patients weighing more than 50 kg with impaired renal function:
Prilagođavanje doze za odrasle bolesnike i adolescente tjelesne težine veće od 50 kg s oštećenom bubrežnom funkcijom: Skupina
• If you suffer from kidney problems, follow your doctor's instructions.
• Ako patite od bubrežnih problema, slijedite upute svog liječnika koji će odlučiti treba li prilagoditi Vašu dozu;
Debossed with "7493" on the other side of the tablet.
Oznaka „7493“ utisnuta je na drugoj strani tablete.
The possible side effects of an overdose of Levetiracetam Teva are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.
Moguće su nuspojave predoziranja Levetiracetamom Teva pospanost, uznemirenost, agresija, smanjena pozornost, smetnje disanja i koma.
However, data suggested a 20 % higher levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products.
Međutim, podaci su pokazali da antiepileptici koji induciraju enzimsku aktivnost kod djece povisuju klirens levetiracetama za 20%.
TEVA UK Ltd Brampton Road Hampden Park Eastbourne East Sussex BN22 9AG United Kingdom
TEVA UK Ltd Brampton Road Hampden Park Eastbourne
Excipient with known effect: Each film-coated tablet contains 0.35 mg colouring agent sunset yellow (E110).
Pomoćna tvar s poznatim učinkom: jedna filmom obložena tableta sadrži 0,35 mg bojila sunset yellow
The NOAEL was < 200 mg/kg/day for the dams and 200 mg/kg/day for the foetuses (equal to the MRHD on a mg/m2 basis).
NOAEL je za gravidne ženke iznosila <200 mg/kg/dan, a za fetuse 200 mg/kg/dan (što je jednako MRHD-u, Maximum Recommended Human Dose, izraženom u mg/m2).
Levetiracetam Teva is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.
Levetiracetam Teva je indiciran kao monoterapija u liječenju parcijalnih napadaja sa sekundarnom generalizacijom ili bez nje u odraslih i adolescenata od 16. godine života s novodijagnosticiranom epilepsijom.
• severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], Quincke's oedema [swelling of the face, lips, tongue and throat]);
• teške alergijske reakcije (DRESS, anafilaktička reakcija [teška i ozbiljna alergijska reakcija],
Adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.
Dodatna terapija u liječenju primarno generaliziranih toničko-kloničkih napadaja u odraslih i adolescenata starijih od navršene 12. godine života s idiopatskom generaliziranom epilepsijom.
Dosing adjustment for infants, children and adolescent patients weighing less than 50 kg with impaired renal function:
Prilagođavanje doze kod dojenčadi, djece i adolescenata s manje od 50 kg tjelesne težine s oštećenom bubrežnom funkcijom: Skupina
Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy.
Dodatna terapija u liječenju parcijalnih napadaja sa sekundarnom generalizacijom ili bez nje u odraslih, adolescenata, djece i dojenčadi od navršenog 1. mjeseca života s epilepsijom.
• as an add-on to other antiepileptic medicines to treat: ■ partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age ■ myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy ■ primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
miokloničkih napadaja (kratki, iznenadni trzaji mišića ili skupine mišića) u odraslih i adolescenata starijih od 12. godine života s juvenilnom miokloničkom epilepsijom; primarno generaliziranih toničko-kloničkih napadaja (veliki napadaji, uključujući gubitak svijesti) u odraslih i adolescenata starijih od 12. godine života s idiopatskom generaliziranom epilepsijom (oblik epilepsije za koji se smatra da je genetski uvjetovan).
Levetiracetam Teva 500 mg contains Tartrazine
Levetiracetam Teva 500 mg sadrži tartrazin
This medicinal product contains colouring agent tartrazine E 102 (see leaflet for further information).
Ovaj lijek sadrži bojilo tartrazin (E102) (vidjeti uputu o lijeku za dodatne informacije).
CLcr (ml/min/1.73 m2) = CLcr (ml/min)__ x 1.73
CLcr (ml/min) CLcr (ml/min/1,73 m2) = -------------------------- x 1,73 PT bolesnika (m2)
An oral solution is the preferred formulation for use in infants and children under the age of 6 years.
Oralna otopina je najprikladniji farmaceutski oblik za primjenu u dojenčadi i djece mlađe od 6 godina.
With continued long-term treatment, 11.4 % of the patients were seizure-free for at least 6 months and 7.2 % were seizure-free for at least 1 year.
S nastavkom dugotrajnog liječenja 11,4% bolesnika bilo je barem 6 mjeseci, a 7,2% barem 1 godinu bez napadaja.
Belgien/Belgique Tél/Tel: +32 3 820 73 73
Teva Pharma Belgium S.A./A.G. Belgien/Belgique Tél/Tel: +32 3 820 73 73
How to store Levetiracetam Teva
Kako čuvati Levetiracetam Teva
In adults, levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1000 mg, 2000 mg, or 3000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks.
Djelotvornost levetiracetama dokazana je u odraslih u 3 dvostruko slijepe i placebom kontrolirane studije gdje su bolesnici tokom liječenja 18 tjedana dobivali 1000 mg, 2000 mg ili 3000 mg/dan,
• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
• u liječenju miokloničkih napadaja u odraslih i adolescenata od 12. godine života s juvenilnom miokloničkom epilepsijom;
This medicinal product contains colouring agent tartrazine (E102) which may cause allergic reactions.
Ovaj lijek sadrži bojilo tartrazin (E 102) koje može uzrokovati alergijske reakcije.
The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighting 50 kg or more, the following formula:
Klirens kreatinina u ml/min može se procijeniti iz serumskog kreatinina (mg/dl), za odrasle i adolescente tjelesne težine
In this study, levetiracetam, dose was 3000 mg/day given in 2 divided doses.
Primijenjena doza kod studije bila je 3000 mg/dan podijeljena na dvije doze.
No adverse reactions on male or female fertility or reproduction performance were observed in rats at doses up to 1800 mg/kg/day (x 6 the MRHD on a mg/m2 or exposure basis) in parents and F1 generation.
Kod mužjaka i ženki štakora roditeljske i F1 generacije nisu primijećene nuspojave na plodnost ili na reprodukciju u dozama do 1800 mg/kg/dan (6-erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2 ili na osnovnu izloženost).
Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
Dodatna terapija u liječenju miokloničkih napadaja u odraslih i adolescenata od navršene 12. godine života s juvenilnom miokloničkom epilepsijom.
The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66 % and 24 % of the dose, respectively during the first 48 hours.
Kumulativno izlučivanje levetiracetama i njegovog glavnog metabolita urinom iznosi 66% odnosno
Excipient with known effect: Each film-coated tablet contains 0.06 mg colouring agent tartrazine (E102).
Pomoćna tvar s poznatim učinkom: jedna filmom obložena tableta sadrži 0,06 mg bojila tartrazina
Levetiracetam Teva 1000 mg film-coated tablets Hypromellose 6 cp, Titanium dioxide (E171), Macrogol 3350
Levetiracetam Teva 1000 mg filmom obložene tablete hipromeloza 6 cp, titanijev dioksid (E171), makrogol 3350
The NOAEL (No Observed Adverse Effect Level) was 3600 mg/kg/day for pregnant female rats (x 12 the MRHD on a mg/m2
NOAEL (No Observed Adverse Effect Level, razina pri kojoj se ne uočava štetni učinak) za gravidne štakorice iznosila je 3600 mg/kg/dan, a za fetuse 1200 mg/kg/dan (12-erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
Levetiracetam Teva 250 mg film-coated tablets Levetiracetam Teva 500 mg film-coated tablets Levetiracetam Teva 750 mg film-coated tablets Levetiracetam Teva 1,000 mg film-coated tablets levetiracetam
Levetiracetam Teva 250 mg filmom obložene tablete Levetiracetam Teva 500 mg filmom obložene tablete Levetiracetam Teva 750 mg filmom obložene tablete Levetiracetam Teva 1000 mg filmom obložene tablete levetiracetam